Equillium, Inc. Insider Trading

Last 12 months

Insiders sold $2.43M and bought nothing on the open market.

70% of the selling was scheduled in advance under 10b5-1 plans. President and CSO Stephen Connelly sold 723K on Jun 5, 23% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$2.43M

0 buys · 11 sales

Under a 10b5-1 plan

70%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

None

in the last two years

Get an email when EQ's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 5	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan	14,584	$2.93	43K	19%	Form 4
Jun 4 – 5	Stephen Connelly President and CSO	SoldNo plan 2 parts	230,975	$3.13 average	723K	23%	Form 4
May 28	Penny Tom Principal Accounting Officer	Sold10b5-1 plan	65,000	$2.95	192K	100%	Form 4
May 27 – 28	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan 4 parts	95,833	$2.79 average	267K	60%	Form 4
Mar 13	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan	120,312	$2.50	301K	66%	Form 4
Mar 9	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan	181,219	$2.00	362K	74%	Form 4
Feb 19	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan 2 parts	185,937	$1.76 average	328K	67%	Form 4
Jan 8	Penny Tom Principal Accounting Officer	Sold10b5-1 plan	6,533	$1.29	8K	100%	Form 4
Dec 23, 2025	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan	100,000	$1.50	150K	52%	Form 4
Dec 12, 2025 – Dec 15, 2025	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan 2 parts	35,704	$1.33 average	47K	28%	Form 4
Nov 25, 2025	Christine Zedelmayer Sr. Vice President and COO	Sold10b5-1 plan 2 parts	8,098	$0.95 average	8K	6.0%	Form 4
Jan 23, 2025	Jason A Keyes Chief Financial Officer	Sold10b5-1 plan	10,000	$0.65	7K	7.3%	Form 4
Nov 14, 2024	Jason A Keyes Chief Financial Officer	Sold10b5-1 plan	10,000	$0.70	7K	7.6%	Form 4

Jun 510b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 14,584 at $2.93
43K
19% of stake
Jun 4 – 5No plan
Stephen Connelly
President and CSO · sold 230,975 at avg $3.13
723K
23% of stake
May 2810b5-1 plan
Penny Tom
Principal Accounting Officer · sold 65,000 at $2.95
192K
100% of stake
May 27 – 2810b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 95,833 at avg $2.79
267K
60% of stake
Mar 1310b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 120,312 at $2.50
301K
66% of stake
Mar 910b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 181,219 at $2.00
362K
74% of stake
Feb 1910b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 185,937 at avg $1.76
328K
67% of stake
Jan 810b5-1 plan
Penny Tom
Principal Accounting Officer · sold 6,533 at $1.29
8K
100% of stake
Dec 23, 202510b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 100,000 at $1.50
150K
52% of stake
Dec 12, 2025 – Dec 15, 202510b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 35,704 at avg $1.33
47K
28% of stake
Nov 25, 202510b5-1 plan
Christine Zedelmayer
Sr. Vice President and COO · sold 8,098 at avg $0.95
8K
6.0% of stake
Jan 23, 202510b5-1 plan
Jason A Keyes
Chief Financial Officer · sold 10,000 at $0.65
7K
7.3% of stake
Nov 14, 202410b5-1 plan
Jason A Keyes
Chief Financial Officer · sold 10,000 at $0.70
7K
7.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EQ, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with EQ

CompareIntrinsic value

NERVMinerva Neurosciences Inc.

$2.57+9.36%10

LXRXLexicon Pharmaceuticals, Inc.

$1.48+1.37%40

CRNXCrinetics Pharmaceuticals Inc.

No recent price40

WVEWave Life Sciences Ltd.

$3.62+1.12%40

INBPIntegrated BioPharma Inc.

$0.17+2.21%28

CUECue Biopharma, Inc.

$19.84-4.89%40

ZYMEZymeworks Inc.

$30.98+2.82%10

ZOMDFZomedica Corp.

$0.09-1.08%46

Held by ETFs

EQ is in 1 US ETF. The largest of them, with EQ's weight in each:

iShares Micro-Cap ETFIWC0.02%of the fund

Spot a number that looks wrong? Check it in EQ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EQ

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.